Organometallic compounds with biological activity: A very selective and highly potent cellular inhibitor for glycogen synthase kinase 3

被引:104
作者
Atilla-Gokcumen, G. Ekin [1 ]
Williams, Douglas S. [1 ]
Bregman, Howard [1 ]
Pagano, Nicholas [1 ]
Meggers, Eric [1 ]
机构
[1] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA
关键词
glycogen synthase kinase 3; medicinal chemistry; organometallic compounds; protein kinases; ruthenium;
D O I
10.1002/cbic.200600117
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A chiral second-generation organoruthenium half-sandwich compound is disclosed that shows a remarkable selectivity and cellular potency for the inhibition of glycogen synthase kinase 3 (GSK-3). The selectivity was evaluated against a panel of 57 protein kinases, in which no other kinase was inhibited to the some extent, with a selectivity window of at least tenfold to more than 1000-fold at 100 mu m ATP Furthermore, a comparison with organic GSK-3 inhibitors demonstrated the superior cellular activity of this ruthenium compound: wnt signaling was fully induced at concentrations down to 30 nM. For comparison, the well-established organic GSK-3 inhibitors 6-bromoindirubin-3'-oxime (BIO) and kenpaullone activate the wnt pathway at concentrations that are higher by around 30-fold and 100-fold respectively. The treatment of zebrafish embryos with the organometallic inhibitor resulted in a phenotype that is typical for the inhibition of GSK-3. No phenotypic change was observed with the mirror-imaged ruthenium complex. The latter does not, in fact, show any of the pharmacological properties for the inhibition of GSK-3, Overall, these results demonstrate the potential usefulness of organometallic compounds as molecular probes in cultured cells and whole organisms.
引用
收藏
页码:1443 / 1450
页数:8
相关论文
共 68 条
[1]   Development of organometallic (organo-transition metal) pharmaceuticals [J].
Allardyce, CS ;
Dorcier, A ;
Scolaro, C ;
Dyson, PJ .
APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10
[2]  
[Anonymous], ANGEW CHEM
[3]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[4]   Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: Discovery of potent and selective protein kinase inhibitors [J].
Bregman, H ;
Carroll, PJ ;
Meggers, E .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (03) :877-884
[5]   Pyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-diones:: Synthesis, cyclometalation, and protein kinase inhibition [J].
Bregman, H ;
Williams, DS ;
Meggers, E .
SYNTHESIS-STUTTGART, 2005, (09) :1521-1527
[6]   An organometallic inhibitor for glycogen synthase kinase 3 [J].
Bregman, H ;
Williams, DS ;
Atilla, GE ;
Carroll, PJ ;
Meggers, E .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (42) :13594-13595
[7]   Chemical inhibitors of protein kinases [J].
Bridges, AJ .
CHEMICAL REVIEWS, 2001, 101 (08) :2541-2571
[8]  
Brunner H, 1999, ANGEW CHEM INT EDIT, V38, P1195, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1194::AID-ANIE1194>3.0.CO
[9]  
2-X
[10]  
Brunner H., 1999, Angew. Chem, V111, P1248